Skip to main content

Year: 2024

HP Inc. Reports Fiscal 2024 Full Year and Fourth Quarter Results

PALO ALTO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — HP (NYSE: HPQ)Fiscal 2024 GAAP diluted net earnings per share (“EPS”) of $2.81, above the previously provided outlook of $2.62 to $2.72 per share Fiscal 2024 non-GAAP diluted net EPS of $3.38, within the previously provided outlook of $3.35 to $3.45 per share Fiscal 2024 net revenue of $53.6 billion, down 0.3% from the prior-year period Fiscal 2024 net cash provided by operating activities of $3.7 billion, free cash flow of $3.3 billion Fiscal 2024 returned $3.2 billion to shareholders in the form of share repurchases and dividends Fourth quarter GAAP diluted net EPS of $0.93, above the previously provided outlook of $0.74 to $0.84 per share Fourth quarter non-GAAP diluted net EPS of $0.93, within the previously provided outlook of $0.89 to $0.99 per share Fourth...

Continue reading

IREN Reports Q1 FY25 Results

50 EH/s expansion accelerated to H1 2025 Focused on alternative funding instruments Potential for investor distributions in 2025 Transition to U.S. domestic issuer SYDNEY, Nov. 26, 2024 (GLOBE NEWSWIRE) — IREN (NASDAQ: IREN) (together with its subsidiaries, “IREN” or “the Company”), today reported its financial results for the first quarter ended September 30, 2024. All $ amounts are in United States Dollars (“USD”) unless otherwise stated. “We are pleased to report our Q1 FY25 results and reiterate our focus on low-cost Bitcoin mining, operating cashflows and shareholder returns,” said Daniel Roberts, Co-Founder and Co-CEO of IREN. “We are just weeks away from achieving our 31 EH/s milestone and are excited to announce the acceleration of our growth trajectory to 50 EH/s in H1 2025, which was previously H2 2025. Our funding program...

Continue reading

Ambarella, Inc. Announces Third Quarter Fiscal Year 2025 Financial Results

SANTA CLARA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — Ambarella, Inc.  (NASDAQ: AMBA), an edge AI semiconductor company, today announced financial results for its third quarter of fiscal year 2025 ended October 31, 2024.Revenue for the third quarter of fiscal 2025 was $82.7 million, up 63% from $50.6 million in the same period in fiscal 2024. For the nine months ended October 31, 2024, revenue was $200.9 million, up 15% from $174.9 million for the nine months ended October 31, 2023. Gross margin under U.S. generally accepted accounting principles (GAAP) for the third quarter of fiscal 2025 was 60.6%, compared with 59.3% for the same period in fiscal 2024.  For the nine months ended October 31, 2024, GAAP gross margin was 60.7%, compared with 60.6% for the nine months ended October 31, 2023.  GAAP net loss for the third quarter...

Continue reading

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Exploration and evaluation of strategic alternatives continue WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024. “We are continuing to explore multiple strategic alternatives to further unlock shareholder value. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions,” said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage. “The ADPORT-601 trial is paused for further patient...

Continue reading

URBN Reports Record Q3 Sales and Earnings

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands including the Anthropologie, Free People, FP Movement, Urban Outfitters and Nuuly brands, today announced record third quarter net income of $102.9 million and earnings per diluted share of $1.10 for the three months ended October 31, 2024. For the nine months ended October 31, 2024, net income was $282.2 million and earnings per diluted share were $2.99. Total Company net sales for the three months ended October 31, 2024, increased 6.3% to a record $1.36 billion. Total Retail segment net sales increased 3.2%, with comparable Retail segment net sales increasing 1.5%. The increase in Retail segment comparable net sales was driven by low single-digit...

Continue reading

Nutanix Reports First Quarter Fiscal 2025 Financial Results

Delivers Outperformance Across All First Quarter Guided Metrics Reports 18% YoY ARR Growth and Strong Free Cash Flow SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced financial results for its first quarter ended October 31, 2024. “During our first quarter we delivered outperformance across our guided metrics,” said Rajiv Ramaswami, President and CEO of Nutanix. “We also continued to bring innovations to the market supporting our vision of becoming the leading platform for running apps and managing data, anywhere, while strengthening our partner ecosystem.” “Our first quarter results demonstrated a good balance of top and bottom line performance with 18% year-over-year ARR growth and strong free cash flow generation,” said Rukmini Sivaraman,...

Continue reading

ASP Isotopes Inc. Responds to Short Seller Report

WASHINGTON, Nov. 26, 2024 (GLOBE NEWSWIRE) — ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today issued the following statement in response to a short seller report published on November 26, 2024 by Fuzzy Panda Research (“Fuzzy Panda”). Fuzzy Panda is a self-proclaimed short seller who stands to realize significant gains if the price of ASP Isotopes’s stock declines. Based upon ASP Isotopes’s and its legal counsel’s preliminary review and evaluation of the report, the Company believes the report includes speculative conjecture and claims that are inaccurate or filled with innuendo in an attempt to mislead investors about ASP Isotopes’s technology, leadership...

Continue reading

Nokia Corporation: Repurchase of own shares on 26.11.2024

Nokia CorporationStock Exchange Release26 November 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 26.11.2024 Espoo, Finland – On 26 November 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.01CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.01* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

Continue reading

Blue Star Foods Announces Stock Buyback Program for Up to $1.5 Million

Miami, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) — Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus on Recirculatory Aquaculture Systems (RAS), today announced a stock buyback program to repurchase up to $1.5 million of the Company’s common stock. Under the program, the Company is authorized to repurchase its shares from time to time in the open market. The timing and amount of any repurchases will depend on a variety of factors, including price, trading volume, general market conditions, and other corporate considerations. The repurchase program does not obligate the Company to repurchase any specific number of shares and may be suspended, modified, or discontinued at any time without prior...

Continue reading

PetVivo to Exhibit Spryng with OsteoCushion™ Technology at the American Association of Equine Practitioners Convention on December 8-10, 2024

MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American Association of Equine Practitioners (“AAEP”) convention to be held December 8th to December 10th, 2024 at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida. PetVivo will exhibit its lead product, Spryng ™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.